As the all-new 2027 Nissan Rogue Hybrid prepares to go on sale in the U.S., its innovative e‑POWER technology has been named ...
Hims & Hers Health is rated a buy, with a fair value estimate of $41 per share versus the current $29.81. Read more on HIMS ...
Overseasexpansion can be categorized into three types: integrating models into the core R&D workflow, co-building a wet‑lab ...
Explore new 2026 cars with 3-cylinder turbo engines, comparing the Chevrolet Trax, Buick Envista, Ford Bronco Sport, Nissan ...
As data platforms and industry analysts converge on the "ontology layer" as the missing piece of agentic AI, MindWalk outlines why life sciences needs a biological context layer of its own, and why ...
In the past, Novo Nordisk A/S (NYSE:NVO) has been a dominant player in diabetes and obesity treatments, with Ozempic and ...
Flagship Pioneering-founded Valo is betting that the AI revolution in drug discovery has been aiming at the wrong target. CEO Brian Alexander ...
"How can we turn peptides that are as effective as injectables into oral drugs?" A clear solution has been proposed for this ...
OpenAIScraps Release of New AI Model Over Safety Concerns The model, dubbed GPT-6.1 Astra, was due to debut inside ChatGPT and Codex in October. ---- Novo Ink ...
Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the ...
The key sentence in the company's announcement about its name change is this one: "As part of this, we will embrace the shorthand 'Novo' as our day-to-day name, while Novo Nordisk A/S remains our ...
CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results